CLEC12A and cancer: Hutten et al. showed CLEC12A/CLL-1 on DCs was an efficient and promising vehicle to present antigen to augment specific CD4+ and CD8+ T cell immune response against cancer, simultaneously and that the antibody binding did not influence phenotype and function of DCs [8].